SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-067065
Filing Date
2021-12-22
Accepted
2021-12-22 17:00:23
Documents
15
Period of Report
2021-12-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 5.01: Changes in Control of Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea152867-8k_allarity.htm   iXBRL 8-K 42736
2 ASSET PURCHASE AGREEMENT DATED DECEMBER 17, 2021, BETWEEN ALLARITY THERAPEUTICS ea152867ex10-1_allarity.htm EX-10.1 77821
3 PRESS RELEASE DATED DECEMBER 21, 2021 - ALLARITY THERAPEUTICS CLOSES ITS RECAPIT ea152867ex99-1_allarity.htm EX-99.1 19353
4 GRAPHIC ex99-1_001.jpg GRAPHIC 4005
  Complete submission text file 0001213900-21-067065.txt   342857

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE onq-20211217.xsd EX-101.SCH 3022
6 XBRL LABEL FILE onq-20211217_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE onq-20211217_pre.xml EX-101.PRE 22358
9 EXTRACTED XBRL INSTANCE DOCUMENT ea152867-8k_allarity_htm.xml XML 3762
Mailing Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139
Business Address 210 BROADWAY SUITE 201 CAMBRIDGE MA 02139 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 211513905
SIC: 2834 Pharmaceutical Preparations